申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
公开号:US20030149062A1
公开(公告)日:2003-08-07
A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:
(a) quinazolines of general formula
1
wherein A, B, C, D, X, R
a
, R
b
, R
c
and n are as defined herein,
(b) the compounds
(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,
(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and
(3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or
(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and
(f) EGFR-antisense.
一种治疗呼吸道或肠道炎症性疾病的方法,该方法包括给予以下物质之一:(a) 通式1中A、B、C、D、X、Ra、Rb、Rc和n所定义的喹唑啉类化合物;(b) 化合物(1) 4-[(3-氯-4-氟苯基)氨基]-6-[(4-二甲基氨基-环己基)氨基]-嘧啶-5,4-二氢嘧啶;(2) 4-[(R)-(1-苯乙基)氨基]-6-(4-羟基苯基)-7H-吡咯并[2,3-d]嘧啶;以及(3) 4-[(3-氯-4-(3-氟-4-苄氧基)苯基)氨基]-6-(5-[(2-甲磺酰基乙基)氨基]甲基-呋喃-2-基)喹唑啉;(d) 抗体Cetuximab C225、Trastuzumab、ABX-EGF和Mab ICR-62;以及(f) EGFR-反义RNA。